Drug:
Reaction: DERMATITIS ATOPIC
20260101 - 20261231
No. 1601 - 1700
| No. | safetyreportid |
occurcountry |
patientonsetage |
patientsex 1:M 2:F |
|---|---|---|---|---|
Adverse reaction |
||||
Drug (openfda.generic_name, medicinalproduct) |
||||
| 1601 | 26764558 |
US |
80 | 2 |
Dermatitis atopic, Pruritus, |
||||
DUPILUMAB, |
||||
| 1602 | 26764959 |
US |
53 | |
Dermatitis atopic, Pain of skin, Impaired work ability, Treatment failure, |
||||
NEMOLIZUMAB-ILTO, |
||||
| 1603 | 26765013 |
US |
84 | |
Dermatitis atopic, Product dose omission issue, |
||||
NEMOLIZUMAB-ILTO, NEMOLIZUMAB-ILTO, |
||||
| 1604 | 26765052 |
US |
80 | 2 |
Arthritis, Gait inability, Pruritus, Skin burning sensation, Sleep disorder due to a general medical condition, Dermatitis atopic, |
||||
DUPILUMAB, FLUTICASONE PROPIONATE, IRBESARTAN, LATANOPROST, METOPROLOL SUCCINATE, METOPROLOL SUCCINATE ER TABLETS, |
||||
| 1605 | 26765053 |
US |
2 | |
Dermatitis atopic, Therapeutic response shortened, |
||||
DUPILUMAB, |
||||
| 1606 | 26765187 |
US |
61 | 2 |
Dermatitis atopic, Rash, Histamine intolerance, |
||||
DUPILUMAB, |
||||
| 1607 | 26765189 |
US |
55 | 2 |
Dermatitis atopic, Rash, |
||||
DUPILUMAB, |
||||
| 1608 | 26762662 |
US |
1 | |
Injection site pain, Dermatitis atopic, Dry eye, Eye pruritus, Product preparation issue, |
||||
DUPILUMAB, FINASTERIDE, ERGOCALCIFEROL, CETIRIZINE HYDROCHLORIDE, |
||||
| 1609 | 26762680 |
CO |
17 | 2 |
Suicidal ideation, Rash, Vomiting, Victim of bullying, Dermatitis atopic, |
||||
UPADACITINIB, FLUOXETINE HYDROCHLORIDE, FLUOXETINE, FLUOXETINE HYDROCHLORIDE, FLUOXETINE, |
||||
| 1610 | 26762730 |
US |
17 | 2 |
Dermatitis atopic, Pruritus, Erythema, Skin ulcer, |
||||
DUPILUMAB, |
||||
| 1611 | 26762786 |
US |
1 | |
Dermatitis atopic, |
||||
LEBRIKIZUMAB-LBKZ, LEBRIKIZUMAB-LBKZ, |
||||
| 1612 | 26762807 |
US |
19 | |
Dermatitis atopic, Product dose omission issue, |
||||
NEMOLIZUMAB-ILTO, |
||||
| 1613 | 26762914 |
US |
44 | 2 |
Surgery, Gingival blister, Rash, Rash, Dermatitis atopic, |
||||
UPADACITINIB, UPADACITINIB, UPADACITINIB, |
||||
| 1614 | 26763053 |
US |
2 | |
Dermatitis atopic, Drug ineffective, |
||||
DUPILUMAB, LORAZEPAM, THYROID, PORCINE, CLOPIDOGREL, CLOPIDOGREL BISULFATE, MIRABEGRON, AMPHETAMINE, ONABOTULINUMTOXINA, FLUOCINONIDE, FLUOCINONIDE TOPICAL SOLUTION USP, 0.05%, RIMEGEPANT SULFATE, ONDANSETRON HYDROCHLORIDE, ONDANSETRON, ONDANSETRON TABLETS, PIMECROLIMUS, |
||||
| 1615 | 26763358 |
US |
5 | 2 |
Dermatitis atopic, Therapeutic response shortened, |
||||
DUPILUMAB, |
||||
| 1616 | 26763361 |
US |
37 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 1617 | 26763376 |
US |
77 | 2 |
T-cell lymphoma, Systemic lupus erythematosus, Urinary tract infection, Dermatitis atopic, Pruritus, Rash, Erythema, Skin irritation, Dry eye, |
||||
DUPILUMAB, DUPILUMAB, FEXOFENADINE HYDROCHLORIDE, AMLODIPINE BESYLATE, FAMOTIDINE, FLUTICASONE PROPIONATE, HYDROXYZINE, LORAZEPAM, OMEPRAZOLE, OMEPRAZOLE MAGNESIUM, PREDNISONE, FLUCONAZOLE, NITROFURANTOIN, NITROFURANTOIN MONOHYDRATE/MACROCRYSTALS, NITROFURANTOIN (MONOHYDRATE/MACROCRYSTALS), LOSARTAN POTASSIUM, LOSARTAN, MONTELUKAST, |
||||
| 1618 | 26763377 |
US |
64 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 1619 | 26763451 |
US |
24 | 2 |
Dermatitis atopic, Skin fissures, Pruritus, |
||||
DUPILUMAB, |
||||
| 1620 | 26763468 |
US |
45 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 1621 | 26763531 |
US |
2 | |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 1622 | 26763536 |
US |
2 | |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 1623 | 26763543 |
US |
56 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 1624 | 26763553 |
US |
28 | 1 |
Rash erythematous, Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 1625 | 26763570 |
US |
25 | |
Dermatitis atopic, Pruritus, |
||||
NEMOLIZUMAB-ILTO, |
||||
| 1626 | 26763660 |
US |
28 | 2 |
Dermatitis atopic, Hypersensitivity, |
||||
DUPILUMAB, |
||||
| 1627 | 26763823 |
US |
81 | |
Dermatitis atopic, Product dose omission issue, |
||||
NEMOLIZUMAB-ILTO, |
||||
| 1628 | 26763942 |
US |
27 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 1629 | 26763984 |
US |
17 | 1 |
Dry skin, Erythema, Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 1630 | 26764028 |
US |
1 | 1 |
Dermatitis atopic, Inappropriate schedule of product administration, |
||||
DUPILUMAB, |
||||
| 1631 | 26764041 |
US |
17 | 1 |
Dermatitis atopic, Inappropriate schedule of product administration, |
||||
DUPILUMAB, DUPILUMAB, LISINOPRIL, |
||||
| 1632 | 26764060 |
US |
2 | |
Dry eye, Dermatitis atopic, |
||||
DUPILUMAB, BLACK COHOSH, ERGOCALCIFEROL, BACLOFEN, GABAPENTIN, |
||||
| 1633 | 26757522 |
US |
2 | |
Dermatitis atopic, |
||||
DUPILUMAB, CRISABOROLE, |
||||
| 1634 | 26757687 |
US |
1 | |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 1635 | 26757711 |
US |
39 | 2 |
Injection site pain, Dermatitis atopic, Device issue, Off label use, Exposure via skin contact, Accidental exposure to product, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 1636 | 26757940 |
US |
15 | 2 |
Dermatitis atopic, Drug ineffective, Rash erythematous, Pruritus, Skin burning sensation, |
||||
DUPILUMAB, |
||||
| 1637 | 26757964 |
US |
46 | 1 |
Dermatitis atopic, Dry eye, |
||||
DUPILUMAB, |
||||
| 1638 | 26758212 |
US |
1 | |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 1639 | 26758234 |
US |
19 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 1640 | 26758235 |
US |
28 | 1 |
Dermatitis atopic, Product dose omission issue, |
||||
DUPILUMAB, |
||||
| 1641 | 26758507 |
US |
2 | 2 |
Rash erythematous, Pruritus, Dermatitis atopic, Therapeutic response decreased, |
||||
DUPILUMAB, |
||||
| 1642 | 26758508 |
US |
39 | 2 |
Dermatitis atopic, Product dose omission issue, Incorrect dosage administered, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 1643 | 26758514 |
US |
||
Dermatitis atopic, Therapeutic response decreased, |
||||
DUPILUMAB, |
||||
| 1644 | 26758522 |
US |
47 | 1 |
Dermatitis atopic, Inappropriate schedule of product administration, |
||||
DUPILUMAB, |
||||
| 1645 | 26758528 |
US |
1 | |
Dermatitis atopic, Blister, |
||||
DUPILUMAB, |
||||
| 1646 | 26758778 |
US |
46 | 2 |
Dermatitis atopic, Stress, Multiple allergies, |
||||
DUPILUMAB, |
||||
| 1647 | 26758789 |
US |
16 | 1 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 1648 | 26758804 |
US |
35 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 1649 | 26759049 |
CA |
16 | 2 |
Colitis ulcerative, Illness, Weight decreased, Psoriasis, Dermatitis atopic, Apocrine miliaria, Folliculitis, Nasopharyngitis, Pyrexia, Chills, Headache, Rhinorrhoea, Oropharyngeal pain, Fatigue, Arthralgia, Ageusia, Anosmia, Genital pain, Mouth ulceration, Vulvovaginal ulceration, Product use issue, Asthenia, Decreased appetite, Nausea, Nasal congestion, Infection, Epstein-Barr virus infection, |
||||
INFLIXIMAB, INFLIXIMAB, INFLIXIMAB, INFLIXIMAB, INFLIXIMAB, |
||||
| 1650 | 26759090 |
US |
5 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 1651 | 26759098 |
US |
3 | 1 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 1652 | 26759108 |
US |
2 | |
Dermatitis atopic, Product dose omission issue, Inappropriate schedule of product administration, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 1653 | 26759407 |
US |
2 | |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 1654 | 26759417 |
US |
34 | 1 |
Dermatitis atopic, Erythema, Dry skin, |
||||
DUPILUMAB, |
||||
| 1655 | 26759444 |
US |
8 | 1 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 1656 | 26759455 |
US |
34 | 1 |
Rash pruritic, Rash, Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 1657 | 26759864 |
US |
54 | 2 |
Dermatitis atopic, Pruritus, Headache, Eye pruritus, Erythema, Dry skin, Ocular hyperaemia, |
||||
DUPILUMAB, |
||||
| 1658 | 26759869 |
US |
9 | 1 |
Dermatitis atopic, Food allergy, |
||||
DUPILUMAB, |
||||
| 1659 | 26760207 |
US |
2 | |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 1660 | 26760340 |
US |
18 | |
Dermatitis atopic, Product dose omission issue, |
||||
NEMOLIZUMAB-ILTO, |
||||
| 1661 | 26760565 |
US |
19 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 1662 | 26760568 |
US |
||
Dermatitis atopic, Wound, Drug ineffective, |
||||
NEMOLIZUMAB-ILTO, |
||||
| 1663 | 26760572 |
US |
19 | 1 |
Pruritus, Skin haemorrhage, Dry skin, Skin exfoliation, Skin fissures, Skin weeping, Dermatitis atopic, Product dose omission issue, |
||||
DUPILUMAB, |
||||
| 1664 | 26760968 |
CN |
71 | 2 |
Seasonal allergy, Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 1665 | 26761292 |
US |
1 | |
Dermatitis atopic, Product dose omission issue, |
||||
DUPILUMAB, |
||||
| 1666 | 26761829 |
US |
84 | 1 |
Dermatitis atopic, Off label use, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 1667 | 26761862 |
US |
29 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 1668 | 26762035 |
US |
2 | |
Erythema, Dry skin, Skin exfoliation, Pruritus, Sleep disorder due to a general medical condition, Skin fissures, Skin haemorrhage, Dermatitis atopic, |
||||
DUPILUMAB, DUPILUMAB, ERGOCALCIFEROL, CETIRIZINE HYDROCHLORIDE, |
||||
| 1669 | 26762155 |
US |
2 | |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 1670 | 26752217 |
US |
43 | 1 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 1671 | 26752370 |
US |
16 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 1672 | 26752389 |
US |
41 | 1 |
Skin fissures, Dry skin, Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 1673 | 26752395 |
US |
25 | 2 |
Dermatitis atopic, Dry skin, Skin swelling, Erythema, Product dose omission issue, |
||||
DUPILUMAB, |
||||
| 1674 | 26752405 |
US |
57 | 1 |
Skin burning sensation, Condition aggravated, Pruritus, Rash, Dermatitis atopic, Product use in unapproved indication, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 1675 | 26752411 |
US |
60 | 2 |
Dermatitis atopic, Rash, |
||||
DUPILUMAB, |
||||
| 1676 | 26752677 |
US |
11 | 2 |
Dermatitis atopic, Off label use, |
||||
DUPILUMAB, |
||||
| 1677 | 26752679 |
US |
28 | 1 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 1678 | 26752688 |
US |
1 | 1 |
Dermatitis atopic, Inappropriate schedule of product administration, |
||||
DUPILUMAB, |
||||
| 1679 | 26752832 |
US |
1 | |
Dermatitis atopic, Intentional dose omission, |
||||
DUPILUMAB, |
||||
| 1680 | 26752837 |
US |
13 | 1 |
Dermatitis atopic, Pruritus, Skin fissures, Dry skin, Skin exfoliation, Drug ineffective, |
||||
DUPILUMAB, |
||||
| 1681 | 26752856 |
US |
2 | |
Dermatitis atopic, Rash, |
||||
DUPILUMAB, |
||||
| 1682 | 26753034 |
US |
56 | 2 |
Dermatitis atopic, Pruritus, |
||||
DUPILUMAB, |
||||
| 1683 | 26753043 |
US |
2 | |
Dermatitis atopic, Therapeutic response shortened, |
||||
DUPILUMAB, |
||||
| 1684 | 26753069 |
US |
62 | 2 |
Dermatitis atopic, Pruritus, Rash, Skin discolouration, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 1685 | 26753275 |
US |
19 | 1 |
Discomfort, Sleep disorder due to a general medical condition, Sinusitis, Condition aggravated, Hypersensitivity, Condition aggravated, Dermatitis atopic, Rash, |
||||
DUPILUMAB, |
||||
| 1686 | 26753619 |
US |
33 | 1 |
Nasal congestion, Dermatitis atopic, Eczema, |
||||
DUPILUMAB, |
||||
| 1687 | 26753633 |
US |
1 | |
Skin swelling, Viral infection, Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 1688 | 26753634 |
US |
24 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 1689 | 26753636 |
US |
11 | 1 |
Dermatitis atopic, Therapeutic response decreased, |
||||
DUPILUMAB, |
||||
| 1690 | 26753639 |
US |
59 | 1 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 1691 | 26753644 |
US |
26 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 1692 | 26753963 |
US |
81 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 1693 | 26753973 |
US |
45 | 2 |
Eczema, Injection site pain, Fear of injection, Pruritus, Dermatitis atopic, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 1694 | 26754339 |
US |
89 | 1 |
Dermatitis atopic, Pruritus, |
||||
DUPILUMAB, |
||||
| 1695 | 26754343 |
US |
2 | |
Dermatitis atopic, Surgery, Chemotherapy, |
||||
DUPILUMAB, |
||||
| 1696 | 26754350 |
US |
2 | |
Dermatitis atopic, Product dose omission issue, |
||||
DUPILUMAB, |
||||
| 1697 | 26754352 |
US |
2 | |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 1698 | 26754370 |
US |
59 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 1699 | 26754407 |
US |
27 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 1700 | 26754797 |
GB |
19 | 2 |
Dehydration, Dizziness, Malaise, Nausea, Vomiting, Heart rate increased, Epigastric discomfort, Dermatitis atopic, Product dose omission issue, |
||||
DUPILUMAB, TIRZEPATIDE, |
||||
disclaimer
Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service.
terms
license
last_updated
2026-07-30